Next Article in Journal
Retrospective Practice Review of Treatment of Metastatic Non-Small-Cell Lung Cancer with Second-Line Erlotinib
Previous Article in Journal
Small-Molecule Bcl-2 Antagonists as Targeted Therapy in Oncology
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Residual Cancer Burden in Locally Advanced Breast Cancer: A Superior Tool

by
Z. Nahleh
1,*,
D. Sivasubramaniam
2,
S. Dhaliwal
2,
V. Sundarajan
2 and
R. Komrokji
2
1
Wayne State University, Karmanos Cancer Institute, Detroit, MI, USA
2
University of Cincinnati, Cincinnati, OH, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2008, 15(6), 271-278; https://doi.org/10.3747/co.v15i6.242
Submission received: 5 September 2008 / Revised: 8 October 2008 / Accepted: 13 November 2008 / Published: 1 December 2008

Abstract

Objectives: Locally advanced breast cancer (LABC) poses a difficult clinical challenge with an overall poor long-term prognosis. The strength of the association between tumour characteristics, treatment response, and outcome is not well defined. In the present study, we attempted to gain further insight into LABC by reviewing tumour characteristics of patients treated with neoadjuvant chemotherapy and by studying the association of those characteristics with outcome. We calculated the residual cancer burden (RCB) score obtained at surgery and attempted to study its correlation with event-free survival (EFS) and overall survival (OS). Methods: We studied patients diagnosed primarily with LABC (n = 45). Pathologic and clinical responses were determined. Pathology slides were reviewed. Results: Of the 45 study patients, 9% had stage iib disease; 29%, stage IIIA; 51%, stage IIIB; and 11%, stage IIIC. Inflammatory breast cancer (IBC) was found in 16%. Pathologic complete response (pCR) was achieved in 22% of all patients. None of the patients with IBC achieved pCR. Patients with estrogen receptor–negative (ER−)/progesterone receptor–negative (PR−) tumours were more likely to achieve pCR than were those with ER+/PR+ tumours. Among patients with tumours that overexpressed human epidermal growth factor receptor 2 (HER2/neu), 17% achieved pCR as compared with 25% of patients with non-overexpressing tumours; only 1 patient had received trastuzumab. The RCB scores were calculated in 32 patients and ranged between 0 and 4.6. Conclusions: The present study examined practical issues related to the classification and management of LABC and IBC. The RCB, defined from routine pathology materials, was easily quantifiable. It appears to be a better predictor than pCR of outcome following neoadjuvant chemotherapy in LABC. Higher RCB scores were associated with lower EFS and a lower rate of OS. A continual quest for reliable predictive and correlative prognostic markers, and for better surrogate endpoints for outcome, is essential to advance our understanding of LABC and to improve treatment outcomes.
Keywords: breast cancer; residual disease; pathology; endpoints; locally advanced disease breast cancer; residual disease; pathology; endpoints; locally advanced disease

Share and Cite

MDPI and ACS Style

Nahleh, Z.; Sivasubramaniam, D.; Dhaliwal, S.; Sundarajan, V.; Komrokji, R. Residual Cancer Burden in Locally Advanced Breast Cancer: A Superior Tool. Curr. Oncol. 2008, 15, 271-278. https://doi.org/10.3747/co.v15i6.242

AMA Style

Nahleh Z, Sivasubramaniam D, Dhaliwal S, Sundarajan V, Komrokji R. Residual Cancer Burden in Locally Advanced Breast Cancer: A Superior Tool. Current Oncology. 2008; 15(6):271-278. https://doi.org/10.3747/co.v15i6.242

Chicago/Turabian Style

Nahleh, Z., D. Sivasubramaniam, S. Dhaliwal, V. Sundarajan, and R. Komrokji. 2008. "Residual Cancer Burden in Locally Advanced Breast Cancer: A Superior Tool" Current Oncology 15, no. 6: 271-278. https://doi.org/10.3747/co.v15i6.242

APA Style

Nahleh, Z., Sivasubramaniam, D., Dhaliwal, S., Sundarajan, V., & Komrokji, R. (2008). Residual Cancer Burden in Locally Advanced Breast Cancer: A Superior Tool. Current Oncology, 15(6), 271-278. https://doi.org/10.3747/co.v15i6.242

Article Metrics

Back to TopTop